Nektar Therapeutics (NKTR NASDAQ) stock market data APIs
$57.1174
0.31(0.5%)
as of December 5, 2025
Try our APIs with
free plan!
Nektar Therapeutics Financial Data Overview
Price chart is built with
Anychart
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Prev. Close
57.1174
Open
57.4276
High
57.5308
Low
56.0457
52 wk Range
6.45-66.92
Market Cap
1 157 M
Shares Outstanding
20 342 K
Revenue
62 600 K
EPS
-1.87
Beta
1.281
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nektar Therapeutics (top by weight)
Ticker
100-day Price Change
Weight
POAGX.US
PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND
7.44
(15.17%)
5.33
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nektar Therapeutics data using free add-ons & libraries
Get Nektar Therapeutics Fundamental Data
Nektar Therapeutics Fundamental data includes:
- Net Revenue: 62 600 K
- EBITDA: -135 195 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.1928
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nektar Therapeutics News
New
Top SA Quant rated small-cap stocks as Russell 2000 notches a record close
[Financial term Small Capitalization Stocks on gray and red finance background from graphs, charts. Trend Up and Down, Flat. 3D render] Vladimir Zakharov/iStock via Getty Images The Russell 2000 inde...
Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Monday's ETF with Unusual Volume: IHE
The iShares U.S. Pharmaceuticals ETF is seeing unusually high volume in afternoon trading Monday, with over 670,000 shares traded versus three month average volume of about 47,000. Shares of IHE were...
Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now?
Nektar Therapeutics (NASDAQ:NKTR) is among the hottest SMID-cap stocks so far in 2025. On November 10, Oppenheimer analyst Jay Olson reaffirmed his Outperform rating on Nektar Therapeutics (NASDAQ:NKT...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
